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S U M M A R Y
Background: The inﬂuenza A(H7N9) virus causes a serious disease that threatens human health.
Fatalities associated with human infections caused by this virus are of great public health concern;
however, the possible risk factors are not yet fully known.
Methods: A stratiﬁed sampling method, incorporating household income levels and a random number
table method, was used to select laboratory-conﬁrmed A(H7N9) cases for this study. Eighty-ﬁve patients
were selected randomly from 139 laboratory-conﬁrmed A(H7N9) cases occurring in Zhejiang Province
between March 1, 2013 and June 30, 2014. Data were collected using a standard method. To test the
statistical signiﬁcance among discrete variables, univariate analyses were used to compare two groups.
The Kaplan–Meier product-limit method was used to analyze the patient survival fraction. The Cox
proportional hazards regression model was used to analyze all variables with p  0.05 in the univariate
analysis. Lastly, a stepwise procedure was used to construct a ﬁnal model with a signiﬁcance level of p >
0.10 for removal and p < 0.05 for re-entry.
Results: A total of 85 patients with H7N9 virus infection were identiﬁed. Among these, 30 (35.29%) died.
In the univariate analysis, the following factors were associated with a high risk of inﬂuenza A(H7N9)
case fatality: age 60 years (p = 0.008), low education level (p = 0.030), chronic diseases (p = 0.029), poor
hand hygiene (p = 0.010), time from illness onset to the ﬁrst medical visit (p = 0.029) and to intensive
care unit admission (p = 0.008), an incubation period of 5 days (p = 0.039), a peak C-reactive protein
120 mg/l (p = 0.012), increased initial neutrophil count (p = 0.020), decreased initial lymphocyte count
(p = 0.021), and initial infection of both lungs (p = 0.003). Multivariate analysis conﬁrmed that the
independent predictors of H7N9 virus infection mortality in Zhejiang, China were hand hygiene (hazard
ratio (HR) 5.163, 95% conﬁdence interval (CI) 1.164–22.661), age (HR 1.042, 95% CI 1.007–1.076), and
peak CRP (HR 1.009, 95% CI 1.002–1.016).
Conclusions: Improvements in immunity, early case identiﬁcation and treatment, and personal
protection measures are key to addressing the high human avian inﬂuenza A(H7N9) case fatality rate.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Avian inﬂuenza viruses of high pathogenicity are reported to
have crossed the species barrier and to have caused human avian
inﬂuenza A.1–3 Following human infections with the H5N1, H9N2,* Corresponding author. Fax: +86 571 85177065.
E-mail address: hbxieli@yeah.net (L. Xie).
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).H7N7, H7N2, and H7N3 viruses, the outbreak of a novel respiratory
infection was identiﬁed in China in late February 2013. On March
31, 2013, the novel avian inﬂuenza A(H7N9) was conﬁrmed in a
patient from Shanghai, China.4,5 However, the possible risk factors
for death are not yet fully known. As of January 31, 2015, a total of
504 human cases of H7N9 had been conﬁrmed in Mainland China,
with the H7 and H9 subtypes responsible for more than 180 deaths,
giving a global mortality rate of over 35.71%.6 The H7N9 virus is of
great public health concern and causes a serious disease thatciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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inﬂuenza H5N1 and H7N9 case fatalities have been in people over
the age of 65 years.8
The primary aim of this study was to describe the demographic
characteristics, epidemiological characteristics, clinical features,
and markers of the fatal cases of H7N9 virus infection. The
secondary aim was to identify mortality risk factors by comparing
current H7N9 patients with those who recovered at the same time
from H7N9 virus infection.
2. Materials and methods
2.1. Subject ascertainment
A case was deﬁned as ‘conﬁrmed’ if the presence of the H7N9
virus was veriﬁed by means of real-time reverse transcriptase PCR
assay (qRT-PCR), viral isolation, or serological testing. RNA was
extracted from throat-swab samples using the Viral RNA Mini Kit
(Qiagen) following the manufacturer’s instructions. Real-time RT-
PCR assays, with self-designed speciﬁc primers and probe sets for
detecting H1 to H16 and N1 to N9 subtypes, were then performed
to verify the viral subtypes.9
A stratiﬁed sampling method was used to select laboratory-
conﬁrmed A(H7N9) cases in this study, which incorporated the
monthly income level of the household (high income level >7000
RMB, middle income level 3001–7000 RMB, low income level
3000 RMB) and a random number table method. Eighty-ﬁve
patients were selected randomly from 139 laboratory-conﬁrmed
A(H7N9) cases in Zhejiang Province occurring between March 1,
2013 and June 30, 2014. The cases were classiﬁed into ‘died’ and
‘recovered’ groups according to the ultimate outcome.
2.2. Data collection
Among the cases selected, 85 were interviewed and observed
after hospital discharge between December 1, 2014 and January
31, 2015. The time of survival analysis began on the day of illness
onset and ended at treatment outcome (death or recovery). The
epidemiological investigations of patients were performed based
on ‘‘The epidemiology survey program of human infections with
H7N9 virus’’, issued by the Chinese Center for Disease Control and
Prevention (China CDC).10 Additionally, the collection and
examination of patient specimens followed ‘‘The plan of collection
specimens and laboratory examination of human infections with
H7N9 virus’’, also issued by the China CDC.11
For each conﬁrmed case, ﬁeld epidemiological investigation
teams from the Hangzhou Center for Disease Control and
Prevention (Hangzhou CDC) set up investigation and disease
control measures. The teams assessed the medical records,
interviewed patients when possible (many patients died before
the investigation teams arrived) and their relatives and key
informants, such as villagers and health care workers, to obtain
demographic, epidemiological, and clinical data. Demographic
data included the patient’s age, sex, area of residence, etc.
Epidemiological data were collected regarding health behaviors
such as hand hygiene practices (e.g., antiseptic hand wash,
antiseptic hand rub, or surgical hand antisepsis, and hand-washing
frequently, i.e., after contact with animals, before meals, and after
using the toilet, etc.),12 smoking and drinking habits, direct contact
with poultry or birds during the 14 days before illness onset, and
visiting a market where there were live poultry or birds during the
14 days before illness onset. Clinical data were obtained from
health care facilities, including status of illness onset (e.g.,
symptoms, incubation period, initial lung infection on admission,
and the time of onset), the diagnosis and treatment of disease (time
from illness onset to the ﬁrst medical visit, hospitalization,oseltamivir treatment, admission to the intensive care unit
(ICU), etc.), laboratory testing at admission (initial neutrophil
and lymphocytes counts (%, 109/l), peak C-reactive protein (CRP,
mg/l), etc.), and clinical outcome (death or recovery). The
incubation period was estimated based on the date of reported
close contact with live poultry or birds as the proxy for infection; in
the sensitivity analyses estimates were explored on the basis of
reported exposures to any live animals and on reported visits to
live poultry markets. In the assessment of the incubation period,
cases who could not recall the exact dates of recent live poultry or
bird exposures were not included. All data in this study were
obtained from the standard questionnaires and ofﬁcial case
investigation reports and were entered in duplicate into an
electronic database.
2.3. Statistical analysis
Descriptive statistics were calculated for the laboratory results
and the questionnaire variables. Subjects were divided into two
groups on the basis of death or recovery from illness. The
characteristic differences in the subgroups of human avian
inﬂuenza A(H7N9) cases were compared using the Pearson Chi-
square test, the Fisher’s exact test for comparing proportions, and
the Wilcoxon signed-rank test for comparing medians of continu-
ous variables. The common odds ratios (ORs) and conﬁdence
intervals (CIs) were also calculated. Continuous variables were
summarized as averages and standard variances for those
following a normal distribution, and as medians with the
interquartile ranges (IQR) for those that were non-normally
distributed. Univariate analysis was used to evaluate the
demographic, epidemiological, and clinical factors associated with
H7N9 infection and case fatality. For categorical variables, the
percentages of cases in each category were calculated. The Kaplan–
Meier product-limit method was used to analyze the patient
survival fraction. Patients who were discharged from the hospital
after successful treatment were assumed to have survived after
discharge. Next, the log-rank test was used to compare survival
distributions. To study risk factors in the association between
H7N9 virus infection and mortality, two groups were created:
‘died’ and ‘recovered’. Subsequently, the association between risk
factors and mortality among the cases was assessed using hazard
ratios (HRs) generated by the Cox proportional hazards regression
model, which also analyzed all variables with p  0.05 in the
univariate analysis. A stepwise procedure was then used to
construct a ﬁnal model with a signiﬁcance level of p > 0.10 for
removal and p < 0.05 for re-entry. Based on the minimum statistics
of the Akaike information criterion (AIC), a ﬁnal model was
selected. Hypothesis testing was conducted using a two-sided test,
with an alpha value of 0.05 to indicate statistical signiﬁcance. All
statistical analyses were conducted using R software (version i386
3.1.1).
3. Results
3.1. Baseline characteristics of cases with H7N9 virus infection
As of June 30, 2014, 139 laboratory-conﬁrmed inﬂuenza
A(H7N9) cases had been reported in Zhejiang Province, China. A
total of 85 H7N9 patients were included in this study, among
whom 30 (35.29%) died. Baseline characteristics of the 85 con-
ﬁrmed cases are shown in Tables 1 and 2.
The median age of all cases was 58.00 years (IQR 49–67 years),
and the ratio of males to females was 2.54 to 1. Of note,
70 conﬁrmed cases (82.35%) were aggregated in April 2013 and
January 2014. The majority of cases were the result of poor hand
hygiene (such as not using antiseptic hand wash prepped with 75%
Table 1
Characteristics of the study population
Characteristic All cases
(n = 85)
Patients
who died
(n = 30)
Patients who
recovered
(n = 55)
p-Value
Mean  SD Mean  SD Mean  SD
Age, years 57.32  14.85 63.13  15.62 54.15  13.53 0.007a
Incubation
period, days
5.17  2.44 4.59  2.17 5.53  2.55 0.157a
Peak C-reactive
protein, mg/l
101.03  63.11 119.74  49.27 92.24  65.80 0.115a
Initial neutrophil
count, %
77.37  9.44 80.31  6.87 75.55  10.29 0.015a
Initial lymphocyte
count, %
15.74  6.92 14.00  5.58 17.60  7.37 0.026a
n (%) n (%) n (%)
City of residence
Hangzhou 61 (71.77) 21 (70.00) 40 (72.72) 0.790b
Huzhou 10 (11.77) 2 (6.67) 8 (14.54) 0.483c
Shaoxing 5 (5.88) 3 (10.00) 2 (3.64) 0.340c
Jiaxing 3 (3.53) 1 (3.33) 2 (3.64) 1.000c
Taizhou 2 (2.35) 1 (3.33) 1 (1.82) 1.000c
Wenzhou 2 (2.35) 0 2 (3.64) 0.538c
Jinhua 2 (2.35) 2 (6.67) 0 0.128c
SD, standard deviation.
a Independent samples t-test.
b Pearson Chi-square test.
c Fisher’s exact test.
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other animals, etc.) and a low education level (primary school or
illiterate). Chronic diseases known to be risk factors for severe
inﬂuenza were present in 55 (64.71%) of the patients with an H7N9
virus infection.13 Chronic diseases were reported more often in
patients who died than in patients who recovered. Additionally,
the ratio of males to females for death attributed to H7N9 infection
was 2.33 to 1. Although the case-fatality rate increased from
27.03% in 2013 (10 of 37 cases) to 41.67% in 2014 (20 of 48 cases),
the yearly trend remained relatively constant (p = 0.161) from
2013 to 2014 (Table 2).
3.2. Risk factors associated with case fatality due to H7N9 virus
infection
As shown in Tables 2 and 3, the following factors were
associated with a high risk of death from inﬂuenza A(H7N9): age
60 years (Chi-square = 7.15, p = 0.008), low education level (Chi-
square = 4.68, p = 0.030), chronic diseases (Chi-square = 4.75,
p = 0.029), poor hand hygiene (Chi-square = 6.57, p = 0.010), time
from illness onset to the ﬁrst medical visit (Z = 2.19, p = 0.029),
and time from illness onset to ICU admission (Z = 2.67, p = 0.008).
Of note, the average age of H7N9 patients who died was older than
that of patients in the ‘recovered’ group. However, there were no
differences between the two groups in the time intervals to
hospitalization, oseltamivir treatment, report, laboratory conﬁr-
mation, and treatment outcome after disease onset (p > 0.05). In
addition, there were no differences in the mean incubation period,
time in the outpatient clinic, or in the period of hospitalization for
H7N9 cases between the two groups (p > 0.05).
Table 4 shows the clinical factors associated with H7N9
infection and mortality. Among the 85 cases, the most common
initial symptoms were fever, cough, and chills. A high spiking fever
was common, and the initial white blood cell, neutrophil, and
lymphocyte counts were normal, increased, and decreased,
respectively. Pulmonary infection was based on bilateral lungs
at the initial stage. From the univariate analysis, the following risk
factors for H7N9 case fatality were identiﬁed: an incubation
period of 5 days (Chi-square = 4.24, p = 0.039), peak CRP120 mg/l (Chi-square = 6.26, p = 0.012), increased initial neu-
trophil count (Chi-square = 5.44, p = 0.020), decreased initial
lymphocyte count (Chi-square = 5.30, p = 0.021), and the presence
of initial infection of the bilateral lungs (Chi-square = 8.58,
p = 0.003). Moreover, the mean initial neutrophil count in the
patients who died was higher than that in those who recovered
(t’ = 2.49, p = 0.015), and the mean initial lymphocyte count in
those who died was lower than that in those who recovered
(t = 2.28, p = 0.026). The ﬁrst symptom, body temperature peak,
initial white blood cell count, initial hemoglobin value, and initial
blood platelet count, were not associated with death from
inﬂuenza A(H7N9) (p > 0.05).
Figure 1 shows survival curves for those who did or did not
implement eligible hand hygiene, such as using antiseptic
handwash prepped with 75% alcohol, washing hands frequently
after contacting poultry or other animals, and so on (Chi-
square = 4.21, p = 0.040). Poor hand hygiene was more common
in patients who died than in those who survived (p = 0.013). The
survival curve for cases with a peak CRP 120 mg/l compared with
a peak CRP <120 mg/l, demonstrates evidence of a survival
difference between these two groups (Chi-square = 9.90, p = 0.002)
(Figure 2).
As shown in Table 5, the independent predictors of H7N9
mortality indicated by the Cox proportional hazards regression
model were hand hygiene, age, and peak CRP. The adjusted HRs for
these three variables indicated that hand hygiene was the highest
risk factor (HR 5.163, 95% CI 1.164–22.661). In addition, the
association of hand hygiene, age, peak CRP, education level, and
initial neutrophil count with the risk of fatal H7N9 virus infection
approached a signiﬁcance of p < 0.10. The incubation period
(p = 0.27) and chronic diseases (p = 0.21), etc., were found to be
non-signiﬁcant predictors and were thus dropped from the ﬁnal
multivariate model.
4. Discussion
In this retrospective study of human avian inﬂuenza A(H7N9)
cases, three independent risk factors for mortality of H7N9 cases in
Zhejiang Province, China were reasonably identiﬁed: hand
hygiene, age, and peak CRP. It was found that variables usually
considered as potential risk factors in previous research, such as
time from illness onset to oseltamivir treatment and underlying
chronic diseases, were not associated with mortality in the present
study.7,8 This is likely because of other early intervention actions.
Increased awareness of the possibility of H7N9 infection among
health care workers might have enabled earlier treatment,
although the time taken to attend a health care facility was much
the same for all cases. Furthermore, the reason for no relationship
being found between initial oseltamivir treatment and mortality
might be because both groups used oseltamivir very late. It is
known that survival improves with earlier antiviral treatment with
oseltamivir.14,15 Oseltamivir treatment should be given as soon as
possible to all patients with a suspected H7N9 infection. However,
most patients in this study received oseltamivir treatment very
late – at a median of 6 days after illness onset – although they
presented early to clinicians with an inﬂuenza-like illness.
Most importantly, this study suggests that poor hand hygiene
was the most signiﬁcant risk factor, which is due to a lack of health
education and knowledge among H7N9 patients and ineffectively
implemented personal protection measures. An analysis of the
reasons for this revealed that they might have poor living
conditions, insufﬁcient health awareness and knowledge, and
unfavorable living habits. These factors affected the morbidity and
mortality of patients with H7N9 virus infection. It is well known
that a high viral load is associated with the severity of illness and
the prognosis.16,17 The high viral load in patients who died with
Table 2
Demographic and epidemiological characteristics of patients with H7N9 virus infections who died and those who recovered in Zhejiang Province, China during 2013–2014
Characteristics All cases Death cases Recovery cases p-Value OR(95%CI)
%(N/85) %(N/30) %(N/55)
Gender
Male 71.76(61/85) 70.00(21/30) 72.73(40/55) 0.790a 0.88(0.33-2.29)
Female 28.24(24/85) 30.00(9/30) 27.27(15/55)
Onset time (year)
2013 43.53(37/85) 33.33(10/30) 49.09(27/55) 0.161a 0.52(0.21-1.29)
2014 56.47(48/85) 66.67(20/30) 50.91(28/55)
Incidence area(city)
Hangzhou 71.76(61/85) 72.41(22/30) 70.91(39/55) 0.812a 1.13(0.42-2.99)
Outside of Hangzhou 28.24(24/85) 27.59(8/30) 29.09(16/55)
Age(yrs.)
60 47.06(40/85) 66.67(20/30) 36.36(20/55) 0.008a 3.50(1.39-8.83)
<60 52.94(45/85) 33.33(10/30) 63.64(35/55)
Type of residence
Urban 70.59(60/85) 73.33(22/30) 69.09(38/55) 0.682a 1.23(0.46-3.24)
Rural 29.41(25/85) 26.67(8/30) 30.91(17/55)
Profession
The retired 24.71(21/85) 30.00(9/30) 21.82(12/55) 0.403a 1.54(0.57-4.15)
Bird and/or poultry transporters or sellers 15.29(13/85) 10.00(3/30) 18.18(10/55) 0.493b 0.50(0.08-2.19)
Workers 16.47(14/85) 20.00(6/30) 14.54(8/55) 0.517a 1.47(0.48-4.56)
Peasants 28.24(24/85) 30.00(9/30) 27.27(15/55) 0.790a 1.14(0.44-3.00)
Of no formal professions 11.76(10/85) 10.00(3/30) 12.73(7/55) 0.984b 0.76(0.12-3.70)
Driver 1.18(1/85) 0.00(0/30) 1.82(1/55) 1.000c NA
Security personnel 2.35(2/85) 0.00(0/30) 3.64(2/55) 0.538c NA
Education level
Primary school or illiteracy 61.18(52/85) 76.67(23/30) 52.73(29/55) 0.030a 2.95(1.10-7.81)
Junior middle school or higher 38.82(33/85) 23.33(7/30) 47.27(26/55)
Chronic diseases
Yes 64.71(55/85) 80.00(24/30) 56.36(31/55) 0.029a 3.10(1.12-8.52)
No 35.29(30/85) 20.00(6/30) 43.64(24/55)
Surgery
Yes 23.53(20/85) 20.00(6/30) 25.45(14/55) 0.571a 0.73(0.26-2.11)
No 76.47(65/85) 80.00(24/30) 74.55(41/55)
Hand hygiene
Eligible 22.35(19/85) 6.67(2/30) 30.91(17/55) 0.010a 0.16(0.02-0.77)
Poor 77.65(66/85) 93.33(28/30) 69.09(38/55)
Smoking
Yes 45.88(39/85) 46.67(14/30) 44.44(25/55) 0.915a 1.05(0.43-2.54)
No 54.12(46/85) 53.33(16/30) 55.56(30/55)
Drinking
Yes 51.76(44/85) 46.67(14/30) 54.55(30/55) 0.487a 0.73(0.30-1.76)
No 48.24(41/85) 53.33(16/30) 45.45(25/55)
Direct contact with poultry or birds during the 14 days before illness onset
Yes 61.18(52/85) 63.33(19/30) 60.00(33/55) 0.763a 1.15(0.46-2.85)
No 38.82(33/85) 36.67(11/30) 40.00(22/55)
Visiting the market where live poultry or birds during the 14 days before illness onset
Yes 75.29(64/85) 76.67(23/30) 74.55(41/55) 0.829a 1.12(0.40-3.09)
No 24.71(21/85) 23.33(7/30) 25.45(14/55)
SD, standard deviation; NA, not available.
a Pearson Chi-square test was used.
b Pearson’s Chi-squared test with Yates’ continuity correction.
c Fisher’s exact test was used.
Table 3
Time characteristics of diagnosis and treatment in patients with H7N9 virus infections who died or who recovered in Zhejiang Province, China during 2013–2014
Characteristics All cases
(n = 85)
Median (IQR)
Patients who died
(n = 30)
Median (IQR)
Patients who recovered
(n = 55)
Median (IQR)
p-Valuea
Time from illness onset to the ﬁrst medical visit, days 1.00 (1.00–2.00) 1.00 (0.00–2.00) 1.00 (1.00–3.00) 0.029
Time from illness onset to hospitalization, days 5.00 (3.00–6.00) 4.00 (2.00–6.00) 5.00 (4.00–6.00) 0.065
Time from illness onset to oseltamivir treatment, days 6.00 (4.00–7.00) 6.00 (4.00–7.00) 6.00 (5.00–8.00) 0.107
Time from illness onset to admission to the ICU, days 6.00 (5.00–8.00) 5.00 (3.00–7.00) 7.00 (6.00–8.00) 0.008
Time from illness onset to laboratory conﬁrmation, days 8.00 (6.00–10.00) 8.00 (6.25–9.75) 8.00 (6.00–10.00) 0.857
Time from illness onset to report, days 7.00 (5.00–9.00) 7.00 (6.00–9.00) 7.00 (5.00–9.00) 0.579
Time from illness onset to treatment outcome, days 28.00 (20.00–39.00) 27.00 (21.00–38.00) 28.00 (20.00–39.00) 0.487
Period in the outpatient clinic, days 1.00 (0.00–2.00) 0.50 (0.00–2.00) 1.00 (0.00–3.00) 0.054
Period of hospitalization, days 24.00 (15.00–33.00) 24.50 (15.00–34.00) 24.00 (14.00–33.00) 0.636
IQR, interquartile range; ICU, intensive care unit.
a The Wilcoxon rank-sum test was used.
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Table 4
Clinical characteristics of patients with H7N9 virus infections who died and those who recovered in Zhejiang Province, China during 2013–2014
Characteristics All cases Death cases Recovery cases p-Value OR(95%CI)
%(N/85) %(N/30) %(N/55)
First symptom
Fever 67.06(57/85) 60.00(18/30) 70.91(39/55) 0.307a 0.62(0.24-1.55)
Cough 44.71(38/85) 40.00(12/30) 47.27(26/55) 0.519a 0.74(0.31-1.82)
Sputum 16.47(14/85) 10.00(3/30) 20.00(11/55) 0.378b 0.45(0.07-1.91)
Chills 29.41(25/85) 20.00(6/30) 34.55(19/55) 0.160a 0.47(0.17-1.33)
Fatigue 21.18(18/85) 20.00(6/30) 21.82(12/55) 0.845a 0.90(0.30-2.62)
Chest tightness 7.06(6/85) 10.00(3/30) 5.45(3/55) 0.735b 1.91(0.24-15.25)
Muscle soreness 9.41(8/85) 13.33(4/30) 7.27(4/55) 0.599b 1.95(0.33-11.35)
Headache 5.87(5/85) 10.00(3/30) 3.64(2/55) 0.478b 2.90(0.31-36.74)
Shortness of breath 3.53(3/85) 6.67(2/30) 1.82(1/55) 0.587b 2.79(0.19-231.32)
Incubation period (days)
5 60.34(35/58) 77.27(17/22) 50.00(18/36) 0.039a 3.40(1.06-10.79)
>5 39.66(23/58) 22.73(5/22) 50.00(18/36)
Body temperature peak
37.3-39 8C 28.24(24/85) 26.67(8/30) 29.09(16/55) 0.812a 0.89(0.33-2.36)
39.1-41 8C 71.76(61/85) 73.33(22/30) 70.91(39/55)
The peak of C-reactive protein(mg/L)
120 48.08(25/52) 70.00(14/20) 34.38(11/32) 0.012a 4.45(1.37-14.47)
<120 51.92(27/52) 30.00(6/20) 65.62(21/32)
Initial white blood cell count(109/L)
Decreased 30.95(26/84) 20.69(6/29) 36.36(20/55) 0.140a 0.46(0.16-1.28)
Normal 63.10(53/84) 72.41(21/29) 58.18(32/55) 0.199a 1.89(0.72-4.90)
Increased 5.95(5/84) 6.90(2/29) 5.46(3/55) 1.000b 1.28(0.10-11.89)
Initial neutrophil count(%,109/L)
Increased 78.05(64/82) 92.86(26/28) 70.37(38/54) 0.040b 5.38(1.11-52.19)
Normal 21.95(18/82) 7.14(2/28) 29.63(16/54)
Initial lymphocytes count(%,109/L)
Decreased 67.95(53/78) 83.33(25/30) 58.33(28/48) 0.021a 3.57(1.20-10.53)
Normal 32.05(25/78) 16.67(5/30) 41.67(20/48)
Initial value of hemoglobin(g/L)
Decreased 29.41(5/17) 33.33(2/6) 27.27(3/11) 1.000c NA
Normal 70.59(12/17) 66.67(4/6) 72.73(8/11)
Initial blood platelet count(109/L)
Decreased 12.12(4/33) 7.14(1/14) 15.79(3/19) 0.620c NA
Normal 87.88(29/33) 92.86(13/14) 84.21(16/19)
Initial lung infection
Infection of bilateral lungs 58.82(50/85) 80.00(24/30) 48.15(26/55) 0.003a 4.46(1.61-12.27)
Infection of single lung 41.18(35/85) 20.00(6/30) 51.85(29/55)
SD, standard deviation; NA, not available.
a Pearson Chi-square test was used.
b Pearson’s Chi-squared test with Yates’ continuity correction.
c Fisher’s exact test was used.
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hygiene and self-protection measures after contact with poultry or
other animals. To decrease mortality rates, it is important that
appropriate hand hygiene is carried out by the susceptible
population after direct contact with poultry or birds.
It could be inferred that the greater the age, the greater the risk
of death. This appears particularly relevant in the H7N9 patients
who died in the present study. The key reason for the high
mortality in elderly patients with severe inﬂuenza A virusFigure 1. Survival plot for patients with poor hand hygiene (blue dashed line)
compared to patients applying adequate hand hygiene (black solid line), by
duration since illness onset.infections may be diminished immune function caused by
underlying chronic diseases.8,18 The age characteristics seen in
the present study were similar to those of seasonal inﬂuenza,19 but
differed from the age characteristics of patients who died from
H5N1 virus infections and those with pandemic H1N1 virus
infections.20,21 Gao et al.7 and Yu et al.18 reported that the risk of
death increased among patients aged 65 years. This is in
agreement with the present study. The World Health Organization,
however, reported that the risk of death was increased amongFigure 2. Survival plot for patients with a peak C-reactive protein 120 mg/l (blue
dashed line), compared to patients with a peak C-reactive protein <120 mg/l (black
solid line), by duration since illness onset.
Table 5
Cox proportional hazards regression model of risk factors for mortality with inﬂuenza A(H7N9) virus infection in Zhejiang Province, China
Characteristics Coefﬁcient HR (95% CI) Standard error
(coefﬁcient)
Wald p-Value
Education level 1.286 0.276 (0.073–1.041) 0.676 1.90 0.057
Peak CRP 0.009 1.009 (1.002–1.016) 0.004 2.16 0.031
Hand hygiene 1.642 5.163 (1.164–22.661) 0.821 2.00 0.045
Initial neutrophil count 0.053 1.054 (0.986–1.122) 0.032 1.65 0.099
Age 0.041 1.042 (1.007–1.076) 0.018 2.31 0.021
HR, hazard ratio; CI, conﬁdence interval; CRP, C-reactive protein.
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A virus infection is more common in immunocompromised
patients including the elderly and children.
Unlike previous studies on human cases of avian inﬂuenza A
virus infection,8 the present ﬁndings showed that a peak CRP of
120 mg/l or higher was signiﬁcantly associated with case fatality.
Although CRP as a serum marker is highly predictive of
cardiovascular events,23,24 the intimal expression of CRP in
clinically relevant acute respiratory distress syndrome (ARDS) is
unknown. It is well known that CRP is a classic acute phase protein.
It can be concluded that a higher CRP value may result from a more
severe H7N9 virus infection. However, it should be recognized that
an increase in CRP level may not be speciﬁc to inﬂuenza virus
infection, and that other infectious processes might have even
greater increases.25 It is likely that the increase in CRP levels also
had signiﬁcant elevations, since all had severe acute infectious
illnesses with unidentiﬁed pathogens;26 however, unidentiﬁed
pathogens include bacterial infections, viral infections, etc. The
results illustrate that a signiﬁcant increase in CRP levels, as
documented for bacterial infections, can also occur with viral
infections.27
The risk factors mentioned previously are possible causes of the
virus’s high fatality rate. Measures aimed at health education, early
disease identiﬁcation, and treatment should be implemented. Staff
training and the equipping of all H7N9 referral hospitals are in
progress to address these issues. Although early treatment is
important, early identiﬁcation of suspected cases for treatment
remains difﬁcult because of the common occurrence of inﬂuenza-
like illnesses and H7N9 in patients who come into frequent contact
with poultry. The ﬁrst symptoms of H7N9 virus infection mostly
lack speciﬁcity. Therefore, many patients may be misdiagnosed
with other inﬂuenza-like illnesses. Increasing access to tests in
basic medical units might improve early identiﬁcation and the
start of oseltamivir treatment. While awaiting laboratory test
results, the systematic treatment with oseltamivir of all patients
with an inﬂuenza-like illness who have had contact with poultry
(without deﬁnitive evidence of exposure) should be carried out,
although there might be problems with capacity. The medical
records should include a thorough history of contact with poultry
or birds (especially sick and dead poultry or birds) for all cases with
an inﬂuenza-like illness. Decreased immune function was also
found to be a predictor of a poor outcome. These measures will
promote earlier detection and treatment of patients and reduce
case fatality.
There are some limitations to this study. First, the data for most
but not all patients with a laboratory-conﬁrmed illness were
included, which restricted the ability of the study to uncover
signiﬁcant variables. Second, for some cases, family members
responded to the interview, and it is possible that they were less
likely to be aware of speciﬁc exposures and activities; this may
have resulted in data bias. Third, there may be recall bias as well,
since participants in the study were asked about risk factors that
had occurred 6 months before the survey. Finally, despite the use of
a standardized data collection form, not all of the required
information was collected for each patient.In conclusion, improvements in immunity, early case identiﬁ-
cation and treatment, and personal protection measures are key to
addressing the high case-fatality rate of H7N9 virus infections.
Ongoing education of the public for behavioral changes is needed
in order to decrease the case fatality risk of the inﬂuenza A(H7N9)
virus. Signiﬁcant health promotion activities regarding inﬂuenza
prevention have been prominent.28 There is a clear need to identify
deﬁnite causes of the high case fatality rate. Further efforts are
needed to develop better diagnostic methods for the early
identiﬁcation of cases, to increase sensitivity of case detection,
and to improve case management before and during hospitaliza-
tion. Finally, all medical institutions and their staff should be
trained in case management of early H7N9 virus infection and be
equipped with oseltamivir for timely administration.
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